<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Klupt S</submitter><funding>NCI NIH HHS</funding><funding>Scripps Research Institute</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><pagination>RP95297</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11164530</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13</volume><pubmed_abstract>&lt;i>Enterococcus faecium&lt;/i> is a microbiota species in humans that can modulate host immunity (Griffin and Hang, 2022), but has also acquired antibiotic resistance and is a major cause of hospital-associated infections (Van Tyne and Gilmore, 2014). Notably, diverse strains of &lt;i>E. faecium&lt;/i> produce SagA, a highly conserved peptidoglycan hydrolase that is sufficient to promote intestinal immunity (Rangan et al., 2016; Pedicord et al., 2016; Kim et al., 2019) and immune checkpoint inhibitor antitumor activity (Griffin et al., 2021). However, the functions of SagA in &lt;i>E. faecium&lt;/i> were unknown. Here, we report that deletion of &lt;i>sagA&lt;/i> impaired &lt;i>E. faecium&lt;/i> growth and resulted in bulged and clustered enterococci due to defective peptidoglycan cleavage and cell separation. Moreo</pubmed_abstract><journal>eLife</journal><pubmed_title>Secreted antigen A peptidoglycan hydrolase is essential for &lt;i>Enterococcus faecium&lt;/i> cell separation and priming of immune checkpoint inhibitor therapy.</pubmed_title><pmcid>PMC11164530</pmcid><funding_grant_id>David C. Fairchild Endowed Fellowship</funding_grant_id><funding_grant_id>R01 CA245292</funding_grant_id><funding_grant_id>Start-up funds</funding_grant_id><funding_grant_id>S10 OD032467</funding_grant_id><funding_grant_id>CA245292</funding_grant_id><pubmed_authors>Chodisetti PK</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Grotjahn D</pubmed_authors><pubmed_authors>Boyd T</pubmed_authors><pubmed_authors>Fam KT</pubmed_authors><pubmed_authors>Mehmood A</pubmed_authors><pubmed_authors>Hang HC</pubmed_authors><pubmed_authors>Park D</pubmed_authors><pubmed_authors>Klupt S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Secreted antigen A peptidoglycan hydrolase is essential for &lt;i>Enterococcus faecium&lt;/i> cell separation and priming of immune checkpoint inhibitor therapy.</name><description>&lt;i>Enterococcus faecium&lt;/i> is a microbiota species in humans that can modulate host immunity (Griffin and Hang, 2022), but has also acquired antibiotic resistance and is a major cause of hospital-associated infections (Van Tyne and Gilmore, 2014). Notably, diverse strains of &lt;i>E. faecium&lt;/i> produce SagA, a highly conserved peptidoglycan hydrolase that is sufficient to promote intestinal immunity (Rangan et al., 2016; Pedicord et al., 2016; Kim et al., 2019) and immune checkpoint inhibitor antitumor activity (Griffin et al., 2021). However, the functions of SagA in &lt;i>E. faecium&lt;/i> were unknown. Here, we report that deletion of &lt;i>sagA&lt;/i> impaired &lt;i>E. faecium&lt;/i> growth and resulted in bulged and clustered enterococci due to defective peptidoglycan cleavage and cell separation. Moreo</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jun</publication><modification>2026-07-15T13:50:29.128Z</modification><creation>2026-07-05T03:11:20.426Z</creation></dates><accession>S-EPMC11164530</accession><cross_references><pubmed>38857064</pubmed><doi>10.7554/eLife.95297</doi></cross_references></HashMap>